PRSS21 Biomarker Detection for AML Immunotherapy Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute myeloid leukemia (AML), particularly the unfavorable subtype acute megakaryoblastic leukemia (AMKL), lack effective immunotherapy targets and biomarkers for precise diagnosis and prognosis, especially in pediatric patients.
Innovation Solution
The use of protease serine 21 (PRSS21) as a biomarker for identifying cancer, including AML and B-cell acute lymphoblastic leukemia, through measuring its expression levels in biological samples using detection agents like nucleic acid probes or antibodies, and administering immunotherapeutic compositions such as CAR-T cell therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If targeted therapies are used for AML, then treatment outcomes are improved, but effective immunotherapy targets are still not available for pediatric AML particularly unfavorable subtypes
Solution Approach 1:
The patent performs preliminary identification and validation of PRSS21 as a therapeutic target through expression analysis in pediatric AML samples before developing immunotherapies. This preliminary characterization of PRSS21 expression patterns and its association with unfavorable AML subtypes enables future immunotherapy development针对specific patient populations.
Solution Approach 2:
The patent introduces PRSS21 as an intermediary biomarker that connects patient characterization with therapeutic selection. By establishing PRSS21 expression as a measurable intermediate parameter, the patent enables identification of suitable candidates for future immunotherapies and provides a basis for personalized treatment strategies.
2Adaptability or versatility
If precise biomarkers are developed for identifying immunotherapy candidates, then treatment personalization is improved, but current diagnostic capabilities lack specific biomarkers for unfavorable AML subtypes
Solution Approach 1:
The patent extracts PRSS21 expression levels as a specific diagnostic biomarker from the complex landscape of AML molecular characteristics. By focusing on this single extracted parameter that distinguishes unfavorable subtypes, the patent creates a practical diagnostic tool for identifying patients who may benefit from immunotherapy.
Solution Approach 2:
The patent replaces traditional morphology-based classification systems with molecular expression analysis of PRSS21. This substitution transitions from visual/mechanical assessment to precise molecular measurement, enabling more accurate identification of unfavorable AML subtypes and immunotherapy candidates.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables accurate diagnosis, prognosis, and targeted therapy for AML and other cancers associated with elevated PRSS21 expression, improving treatment outcomes for patients by identifying suitable candidates for immunotherapy and personalizing cancer treatment.
Implementation Method 1
measuring the level of PRSS21 in a biological sample by contacting the biological sample with a PRSS21 detection agent
Data Source
AI summary
Methods for detection, diagnosis, prognosis, theragnosis, and targeted therapy of a PRSS21-overexpressing condition (e.g., cancer), in particular, PRSS21-overexpressing acute myeloid leukemia of the AMKL subtype.